BofA/Merrill Lynch Downgrades Achillion Pharmaceuticals (ACHN) to Underperform

September 30, 2013 6:45 AM EDT Send to a Friend
Get Alerts ACHN Hot Sheet
Price: $14.20 +9.91%

Rating Summary:
    13 Buy, 2 Hold, 1 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 0 | Down: 5 | New: 5
Trade ACHN Now!
Join SI Premium – FREE
BofA/Merrill Lynch downgraded Achillion Pharmaceuticals (NASDAQ: ACHN) from Buy to Underperform.

For an analyst ratings summary and ratings history on Achillion Pharmaceuticals click here. For more ratings news on Achillion Pharmaceuticals click here.

Shares of Achillion Pharmaceuticals closed at $7.24 yesterday.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Downgrades

Related Entities

Merrill Lynch, Bank of America

Comments

Intersting Call BOA
Joshua on 2013-10-01 10:51:32
Mark as Spam | Reply to this comment

They harshly downgrade the stock but increased their postion by 66K? Sounds a little bit like some sort of FRAUD. But, what should one expect from a big bank like BOA.


Add Your Comment